skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8830

A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia

Original Research

(3703) Views  (1160) Full article downloads

Authors: Amy S Chappell, Laurence A Bradley, Curtis Wiltse, Michael J Detke, Deborah N D’Souza, Michael Spaeth

Published Date December 2008 Volume 2008:1 Pages 91 - 102
DOI: http://dx.doi.org/10.2147/IJGM.S3979

Amy S Chappell1, Laurence A Bradley2, Curtis Wiltse1, Michael J Detke1,3,4, Deborah N D’Souza1, Michael Spaeth5

1Lilly Research Laboratories, Indianapolis, IN, USA; 2University of Alabama at Birmingham, Birmingham, Alabama, USA; 3Indiana University School of Medicine, Indianapolis, IN, USA; 4Harvard Medical School, Boston, MA, USA; 5Practice for Internal Medicine/Rheumatology, Graefelfing, Germany

Objective: Assess the efficacy of duloxetine 60/120 mg (N = 162) once daily compared with placebo (N = 168) in the treatment of patients with fibromyalgia, during six months of treatment.

Methods: This was a phase-III, randomized, double-blind, placebo-controlled, parallel-group study assessing the efficacy and safety of duloxetine.

Results: There were no significant differences between treatment groups on the co-primary efficacy outcome measures, change in the Brief Pain Inventory (BPI) average pain severity from baseline to endpoint (P = 0.053) and the Patient’s Global Impressions of Improvement (PGI-I) at endpoint (P = 0.073). Duloxetine-treated patients improved significantly more than placebo-treated patients on the Fibromyalgia Impact Questionnaire pain score, BPI least pain score and average interference score, Clinical Global Impressions of Severity scale, area under the curve of pain relief, Multidimensional Fatigue Inventory mental fatigue dimension, Beck Depression Inventory-II total score, and 36-item Short Form Health Survey mental component summary and mental health score. Nausea was the most common treatment-emergent adverse event in the duloxetine group. Overall discontinuation rates were similar between groups.

Conclusions: Although duloxetine 60/120 mg/day failed to demonstrate significant improvement over placebo on the co-primary outcome measures, in this supportive study, duloxetine demonstrated significant improvement compared with placebo on numerous secondary measures.

Keywords: fibromyalgia, duloxetine, placebo, double-blind, trial, pain








Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Effects of selective serotonin reuptake inhibitors on motor neuron survival
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Duloxetine for the management of fibromyalgia syndrome
Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia
Development of a vaccine to prevent Japanese encephalitis: a brief review
Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence
Preferences related to attention-deficit/hyperactivity disorder and its treatment
Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan
Lyme disease and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS): an overview
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University